Sensorion Announces Agenda For R&D Day Showcasing Gene Therapy For Inner Ear Disease

Thursday April 6, 2023, at 8am EDT, 2pm CEST Regulatory News: Sensorion, (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies

Related Keywords

United States ,Paris ,France General ,France ,Washington ,Charenton ,America ,Dennis Riedl ,Christine Petit ,Institut Pasteur ,Barbara Kelley ,Necker Enfants Malades ,Nawal Ouzren ,David Lawrence ,Natalie Loundon ,Matthew Cole Jessica Hodgson ,Head Of Preclinical Development ,Hearing Institute Institut ,Communications Europe France ,Hearing Loss Association Of America ,International Media Relations ,Hearing Institute ,Professor At College De France ,Gt Program Laurent ,Consilium Strategic Communications ,Thursday April ,Chief Medical Officer ,Laurent Desire ,Preclinical Development ,Christine Le Bec ,Opinion Leaders ,College De France ,Executive Director ,Hearing Loss Association ,Pediatric Audiology ,Pediatric Otolaryngologist ,Neck Surgeon ,Hearing Loss ,Gene Therapy ,Gene Therapy Clinical Trial ,Lead Gene Therapy Program ,Cisplatin Induced Ototoxicity ,Cochlear Limited ,Sudden Sensorineural Hearing Loss ,Chief Financial Officer ,United Kingdom ,Investor Relations ,Strategic Communications ,Sue Stuart ,Sensorion ,Nnounces ,Agenda ,Howcasing ,Gene ,Therapy ,Banner ,Disease ,